Tasisulam sodium  (Synonyms: LY 573636 sodium)

Tasisulam is a anticancer agent and induces apoptosis via the intrinsic pathway, resulting in cytochrome c release and caspase-dependent cell death. Tasisulam inhibits mitotic progression and induces vascular normalization^[1].

Tasisulam sodium (200 nM-200 μM; 48 hours) induces an antiproliferative response across a wide range of tumor histologies with EC₅₀s of 10 μM and 25 μM for Calu-6 and A-375 cell lines, respectively^[1].
Tasisulam sodium (25, 50 μM; 72 hours) induces a concentration-dependent increase in 4N DNA and G2-M accumulation^[1].
Tasisulam sodium (200 nM-200 μM; 48 hours) induces apoptosis in a broad range of in vitro cancer cell models^[1].
Tasisulam sodium also blocks VEGF, epidermal growth factor, and fibroblast growth factor-induced endothelial cell cord formation^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

437.09

C₁₁H₅BrCl₂NNaO₃S₂

519055-63-1

O=C(N([Na])S(=O)(C1=CC=C(Br)S1)=O)C2=CC=C(Cl)C=C2Cl

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Meier T, et al. Tasisulam sodium, an antitumor agent that inhibits mitotic progression and induces vascular normalization. Mol Cancer Ther. 2011 Nov;10(11):2168-78.  [Content Brief]